5-fluorouracil by protracted subcutaneous infusion. A pilot study.
A feasibility study of 5-fluorouracil (5-FU) delivered by long-term subcutaneous infusion (SCI) was carried out in 10 patients with advanced malignancies refractory to conventional treatment. 5-FU: 200 mg/m2/day was administered by an external infusor (Baxter 5 or 7 Multiday) connected with a 21-gauge needle placed in the thoracic wall. Treatment was continued until progression of disease or toxicity. WHO grade II to III mucositis was experienced by two and one patients, respectively. Grade II diarrhea developed in one patient. Local toxicity was substantial but painless and manageable; skin ulceration was experienced by two patients. A total of 88 weeks of therapy was delivered with a median of 8.8 weeks for each patient (range 2 to 16). Two patients (breast and colorectal cancer) achieved a partial remission; two additional cases showed a > 50% decrease in tumor marker levels. In conclusion, the administration of 5-FU by SCI deserves further evaluation, especially in clinical circumstances in which venous access is limited by thrombosis or technical concerns.
Servizio di Oncologia, Spedali Civili, Brescia, Italy.
A
A
Zaniboni
F
F
Meriggi
A
A
Alghisi
G
G
Marini
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007279:Injections, Subcutaneous / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects
D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil